Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05553353 · ClinicalTrials.gov registry record · NA

Dosing rTMS for Depression Post-SCI

A NA study of Depression and Spinal Cord Injuries, sponsored by VA Office of Research and Development.

Recruiting
Registry status
NA
Development phase
24
Enrollment target
1
Study location

NCT05553353: Recruiting NA study of Depression and Spinal Cord Injuries, sponsored by VA Office of Research and Development.

NCT05553353 is a NA study of Depression and Spinal Cord Injuries that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 24 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05553353, a NA study of Depression and Spinal Cord Injuries, is actively recruiting participants, sponsored by VA Office of Research and Development.

RECRUITING
Registry status
NA
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

Depression is a leading cause of disability worldwide and is more commonly seen in individual's post-spinal cord injury (SCI) than in the general population. Depression post-SCI impacts an individuals' quality of life and recovery. It has been reported that among Veterans with an SCI, those without depression live longer than those with depression. Thus, depression must be treated appropriately. Repetitive transcranial magnetic stimulation (rTMS) is an FDA-approved treatment for depression, but dosing is based on a motor response or movement in the thumb. Over half of individuals with SCI have some degree of arm or hand impairment, so these individuals might not be eligible for rTMS, or they may receive the wrong dose. This study proposes clinical trial in individuals with depression post-SCI to assess the anti-depressant effect of a novel technique to dose rTMS that does not require a motor response in the thumb. By gaining a better understanding of the application of rTMS for depression post-SCI, the investigators aim to advance the rehabilitative care of Veterans.

Primary Outcome

The Hamilton Rating Scale for Depression (HAM-D17) is the most widely used tool to assess the severity of depressive symptoms, once diagnosed, and will be used in this study. The HAM-D17 is a semi-structured interview style questionnaire that asks about one's experience with seventeen different depressive symptoms over the past week. Total HAM-D17 scores range from no depressive symptoms (HAM-D17 = 0-7); mild (HAM-D17 = 8-16), moderate (HAM-D17 = 17-23) or severe depressive symptoms (HAMD-D17 =

Interventions

  • DEVICE repetitive transcranial magnetic stimulation--Active
  • DEVICE repetitive transcranial magnetic stimulation--Sham

Study Locations (1)

South Carolina

  • Ralph H. Johnson VA Medical Center, Charleston, SC - Charleston

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2025-03-31
Est. Completion 2027-10-29
Phase NA
VA Office of Research and Development

1,668 total trials

What NCT05553353 shows while recruiting

NCT05553353 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 786-participant average among 679 other Depression trials with a reported enrollment target (97% lower).

The record links to 3 conditions, with Depression appearing as the primary indexed condition, and to 2 interventions - of which repetitive transcranial magnetic stimulation--Active is the first listed.

NCT05553353 reports a single indexed study location in South Carolina.

Frequently Asked Questions

What is clinical trial NCT05553353 about?

NCT05553353 is a clinical study titled "Dosing rTMS for Depression Post-SCI". Depression is a leading cause of disability worldwide and is more commonly seen in individual's post-spinal cord injury (SCI) than in the general population. Depression post-SCI impacts an individuals' quality of life and recovery. It has been reported that among Veterans with an SCI, those without ...

What is the current status of trial NCT05553353?

This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2025-03-31. Estimated completion is 2027-10-29.

What conditions does trial NCT05553353 study?

This clinical trial studies the following conditions: Depression, Spinal Cord Injuries, Depressive Disorder, Major.

What interventions are being tested in trial NCT05553353?

The interventions under investigation include: repetitive transcranial magnetic stimulation--Active (DEVICE), repetitive transcranial magnetic stimulation--Sham (DEVICE).

Who is sponsoring clinical trial NCT05553353?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05553353 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05553353's enrollment target sits among peer trials

24 594th of 679 higher than 79 of 679 other Depression trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Depression trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT05553353, the US trial registry maintained by the National Library of Medicine. NCT05553353 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.